Elan Alzheimer's Peptide Vaccine To Enter Phase II/III By End Of 2001
Executive Summary
Elan's AN-1792 beta-amyloid peptide for immunization of Alzheimer's patients is expected to reach pivotal Phase II/III trials by the end of 2001, Elan Exec VP and Chief Scientific & Medical Officer Ivan Lieberburg, MD/PhD, told a press conference during the World Alzheimer's Conference in Washington, D.C.
You may also be interested in...
Antigenics To Stimulate Immunology Projects With Stimulon From Aquila
Antigenics expects to boost its infectious disease and autoimmune product development with Aquila's vaccine adjuvant Stimulon QS-21 following a proposed merger.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011